|
Tiragolumab Clinical Trials
9 actively recruiting trials across 5 locations
Also known as: Anti-TIGIT, MTIG7192A, RG-6058, RO7092284, anti-TIGIT
Pipeline
Phase 1: 1Phase 2: 4Phase 3: 1Phase 1/2: 3
Top Sponsors
- Hoffmann-La Roche3
- M.D. Anderson Cancer Center2
- The Netherlands Cancer Institute1
- Omico1
- Alliance Foundation Trials, LLC.1
Indications
- Cancer9
- Squamous Cell Carcinoma2
- Metastatic Malignancy1
- Advanced Liver Cancers1
- Oral Cavity Squamous Cell Carcinoma1
Other3 trials
Houston, Texas2 trials
Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma
M D Anderson Cancer Center
Phase 1/2
Birmingham, Alabama1 trial
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
UAB Comprehensive Cancer Center
Phase 1
Costa Mesa, California1 trial
Duarte, California1 trial
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
City of Hope Comprehensive Cancer Center
Phase 1/2
San Francisco, California1 trial
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
University of San Francisco, California
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.